Annovis Bio, Inc. (ANVS)
Automate Your Wheel Strategy on ANVS
With Tiblio's Option Bot, you can configure your own wheel strategy including ANVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANVS
- Rev/Share 0.0
- Book/Share 940.6871
- PB 0.0036
- Debt/Equity 0.0
- CurrentRatio 6.1068
- ROIC -0.0017
- MktCap 66496819.0
- FreeCF/Share -678.2502
- PFCF -0.005
- PE -2.1766
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0066
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ANVS | D. Boral Capital | Buy | Hold | -- | -- | Feb. 10, 2025 |
News
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD).
Read More
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Annovis to Host Webinar and Live Q&A on June 24, 2025
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
Read More
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
Read More
About Annovis Bio, Inc. (ANVS)
- IPO Date 2020-01-29
- Website https://www.annovisbio.com
- Industry Biotechnology
- CEO Maria L. Maccecchini
- Employees 8